Key facts
- It has raised $5.2M; the latest was Seed Round ($5.2M) in Sep 2025.
- Notable investors include Khanu Management, TU capital, VORNvc, i&i Biotech Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for KyDo Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for KyDo Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KyDo Therapeutics
Operator of a biotechnology company intended to redefine cancer treatment by developing first-in-class covalent-allosteric small molecule inhibitors that overcome resistance mechanisms in oncology. The company offers a pioneering approach to precision oncology through the covalent-allosteric modulation of key cancer drivers, enabling customers to access more effective therapies with reduced side effects and an enhanced potential for combination treatments that address urgent, unmet needs in cancer care.
- Sector
- Healthcare
- HQ
- Dortmund, Germany
- Founded
- 2024
- Employees
- 4
- Website
- kydo-tx.com/
- Ownership
- Privately Held (backing)
KyDo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KyDo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KyDo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.